Last week, we covered the controversial approval of the first Alzheimer’s drug in 20 years. Last year, the FDA advisory committee determined that there wasn’t enough support that the treatment is effective. According to a CNN Health article, one member of the committee has resigned in protest of the recent approval of Biogen’s experimental drug that costs $56k/year.
Alzheimer Drug Approval Leads FDA Advisor to Resign
A Mayo Clinic neurologist resigned in protest of the FDA’s questionable approval of aducanumab.
Jun 15, 2021
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Downloads
